Hormone-refractory Prostate Cancer
📧 Sign up to get email alerts when something new happens for Hormone-refractory Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-05-25Clinical Trial Update: Study Evaluating the Safety and Tolerability of L-377202 [Phase 1, Phase 2]
Phase 1/2 trial evaluating safety and tolerability of L-377202 in hormone refractory and standard prostate cancer has completed.
-
CLINICAL_TRIALS trial_result · 2023-04-19Clinical Trial Update: BAY88-8223, Does Response Study in HRPC Patients [Phase 2]
Phase 2 clinical trial update for BAY88-8223 in hormone-refractory prostate cancer with bone metastases has completed.
-
CLINICAL_TRIALS trial_result · 2021-04-06Clinical Trial Update: Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer [Phase 1, Phase 2]
Phase 1/2 study of sacituzumab govitecan-hziy (IMMU-132) in adults with epithelial cancers; trial completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-12-17Clinical Trial Update: Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer [Phase 2]
Phase 2 clinical trial update on patupilone for metastatic hormone-refractory prostate cancer, reporting efficacy and safety results.
-
CLINICAL_TRIALS trial_result · 2020-05-13Clinical Trial Update: A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients [Phase 1, Phase 2]
Clinical trial update for SHR3680 in metastatic castration-resistant prostate cancer across Phase 1 and Phase 2, with unknown status.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-06-11Clinical Trial Update: Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer [Phase 1, Phase 2]
A phase 1/2 trial evaluating lenalidomide with cyclophosphamide in previously treated hormone-refractory prostate cancer was terminated; res…
-
CLINICAL_TRIALS trial_result · 2018-05-25Clinical Trial Update: Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer [Phase 2]
Phase 2 trial of dasatinib (Sprycel) in hormone-refractory prostate cancer completed; results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2017-06-12Clinical Trial Update: Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer [Phase 2]
Phase 2 trial comparing concurrent versus sequential sipuleucel-T and abiraterone in metastatic castration-resistant prostate cancer has com…
-
CLINICAL_TRIALS trial_result · 2015-04-06Clinical Trial Update: Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer [Phase 3]
A Phase 3 trial update assessing a therapy aimed at prolonging metastasis-free survival in men with hormone-refractory prostate cancer has c…
-
CLINICAL_TRIALS trial_result · 2013-12-05Clinical Trial Update: Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel [Phase 2]
A phase 2 trial evaluating cediranib maleate with or without dasatinib in hormone-refractory prostate cancer that is resistant to docetaxel …
-
FDA approval · 2012-12-05FDA Approved: MITOXANTRONE — Supplemental Application (Meitheal Pharmaceuticals Inc.)
The FDA approved a supplemental application for mitoxantrone from Meitheal Pharmaceuticals Inc., updating the approved generic product under…
-
CLINICAL_TRIALS trial_result · 2011-05-24Clinical Trial Update: E3-Hormone Refractory Prostrate Cancer Taxotere Combination [Phase 2]
Phase 2 clinical trial evaluating a Taxotere (docetaxel) combination for hormone-refractory metastatic prostate cancer has completed with re…
-
FDA label_change · 2009-08-20FDA Approved: MITOXANTRONE — Supplemental Application (Hospira, Inc.)
FDA approved a supplemental application for MITOXANTRONE by Hospira, Inc., resulting in updated labeling for the product under the ANDA. The…